ACVL1, Polyclonal Antibody

ACVL1; ACVRL1; ACVRLK1; ALK-1; Activin receptor-like kinase 1

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Rabbit

The antibody detects endogenous levels of total ACVL1 protein.

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

1.0 mg/ml (lot specific)

Store at -20 degree C

Small volumes of anti-ACVL1 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Type I receptor for TGF-beta family ligands BMP9/GDF2 and BMP10 and important regulator of normal blood vessel development. On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. May bind activin as well.ten Dijke P., Oncogene 8:2879-2887(1993).Attisano L., Cell 75:671-680(1993).Berg J.N., Am. J. Hum. Genet. 61:60-67(1997).

Total protein Ab

Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF)

Western blotting: 1:500~1:3000
Immunohistochemistry: 1:50~1:100
Immunofluorescence: 1:100~1:500

Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using ACVL1 antibody.

Immunofluorescence analysis of HeLa cells, using ACVL1 antibody.

Western blot analysis of extracts from K562 cells, using ACVL1 antibody.

Western blot analysis of extracts from 3T3 cells (Lane 2), using ACVL1 antiobdy. The lane on the left is treated with synthesized peptide.

56,124 Da

activin A receptor type II-like 1

serine/threonine-protein kinase receptor R3

Serine/threonine-protein kinase receptor R3

ACVRLK1; ALK1; SKR3; ALK-1; TSR-I  [Similar Products]

ACVL1_HUMAN

This gene encodes a type I cell-surface receptor for the TGF-beta superfamily of ligands. It shares with other type I receptors a high degree of similarity in serine-threonine kinase subdomains, a glycine- and serine-rich region (called the GS domain) preceding the kinase domain, and a short C-terminal tail. The encoded protein, sometimes termed ALK1, shares similar domain structures with other closely related ALK or activin receptor-like kinase proteins that form a subfamily of receptor serine/threonine kinases. Mutations in this gene are associated with hemorrhagic telangiectasia type 2, also known as Rendu-Osler-Weber syndrome 2. [provided by RefSeq, Jul 2008]

ALK1: a kinase of the STKR family. A type I cell-surface receptor for the TGF-beta superfamily of ligands including Activin A. Highly expressed in human placenta and lung. Deficiency causes hemorrhagic telangiectasia type 2 also known as Rendu-Osler-Weber syndrome 2.

Protein type: EC 2.7.11.30; Kinase, protein; Protein kinase, Ser/Thr (receptor); Protein kinase, TKL; Membrane protein, integral; TKL group; STKR family; Type1 subfamily

Chromosomal Location of Human Ortholog: 12q13.13

Cellular Component: cell surface; cell soma; integral to plasma membrane; dendrite

Molecular Function: transforming growth factor beta receptor activity; protein serine/threonine kinase activity; protein binding; activin receptor activity, type I; transforming growth factor beta receptor activity, type I; transforming growth factor beta binding; metal ion binding; activin binding; SMAD binding; protein kinase binding; ATP binding; transmembrane receptor protein serine/threonine kinase activity; receptor signaling protein serine/threonine kinase activity

Biological Process: protein heterooligomerization; blood circulation; positive regulation of transcription, DNA-dependent; activin receptor signaling pathway; negative regulation of cell adhesion; signal transduction; regulation of blood vessel endothelial cell migration; protein amino acid phosphorylation; BMP signaling pathway; negative regulation of cell proliferation; positive regulation of endothelial cell differentiation; regulation of transcription, DNA-dependent; negative regulation of endothelial cell differentiation; regulation of blood pressure; transforming growth factor beta receptor signaling pathway; lymphangiogenesis; angiogenesis; negative regulation of cell migration; positive regulation of BMP signaling pathway; regulation of DNA replication; regulation of endothelial cell proliferation; in utero embryonic development; negative regulation of focal adhesion formation; negative regulation of blood vessel endothelial cell migration; blood vessel maturation; blood vessel endothelial cell proliferation during sprouting angiogenesis; positive regulation of angiogenesis; positive regulation of chondrocyte differentiation; negative regulation of endothelial cell proliferation; blood vessel remodeling; positive regulation of endothelial cell proliferation; positive regulation of transcription from RNA polymerase II promoter; negative regulation of cell growth; wound healing, spreading of epidermal cells

Disease: Telangiectasia, Hereditary Hemorrhagic, Type 2

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.